ClinicalTrials.gg
CompletedNCT02477618Updated Oct 14, 2025Results posted

A Study With SAGE-547 for Super-Refractory Status Epilepticus

A Phase 3 interventional study of SAGE-547 and Placebo in Super-Refractory Status Epilepticus, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 171 sites in 16 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies in Status Epilepticus with a site in United States — 13 open to participants now, 13 under way, 2 of them phase 3. Status Epilepticus · United States.

Enrollment
8th of 30
132 · median 35
Started
2015
with 2 others
Phase 3
8 of 41
2 open now
Registered
10th of 41
by date
Lead sponsor
2 of 41
Supernus Pharmaceuticals, Inc.

Among the 41 studies in Status Epilepticus with a site in United States, this one is the 8th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2015, is one of 8 in phase 3, and was the 10th registered.

Status Epilepticus

124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.

Browse Status Epilepticus studies →

Open to participants now

13 of the 41 studies in Status Epilepticus with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Status Epilepticus studies recruiting now, 16 (55%) set no upper age limit and 8 (28%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Status Epilepticus with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled trial, designed to evaluate the efficacy and safety of SAGE-547 administered as a continuous intravenous infusion to subjects in Super-Refractory Status Epilepticus (SRSE).

03

Conditions studied

  • Super-Refractory Status Epilepticus

Browse trials for

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects two (2) years of age and older
  • Subjects who have:

    • Failed to respond to the administration of at least one agent (e.g., benzodiazepine or other emergent initial anti-epileptic drug [AED] treatment), according to institution standard of care, and;
    • Failed to respond to at least one second-line agent (e.g., phenytoin, fosphenytoin, valproate, phenobarbital, levetiracetam or other urgent control AED), according to institution standard of care, and;
    • Not previously been administered a third-line agent but have been admitted to an intensive care unit with the intent of administering at least one third-line agent for at least 24 hours; or who have previously failed zero, one or more wean attempts from third-line agents and are now on continuous intravenous infusions of one or more third-line agent and in an EEG burst or seizure suppression pattern; or who have previously failed one or more wean attempts from third-line agents and are now either not on a continuous intravenous infusion of at least one third-line agent or are on a continuous intravenous infusion of one or more third-line agent but not in an EEG burst or seizure suppression pattern

Exclusion criteria

Exclusion Criteria:

  • Subjects with SRSE due to anoxic/hypoxic encephalopathy with highly malignant/ malignant EEG features
  • Children (subjects aged less than 17 years) with an encephalopathy due to a rapidly progressing underlying neurological disorder
  • Subjects who have any of the following:

    1. a (GFR) low enough to warrant dialysis but for whatever reason, dialysis is not planned or non-continuous dialysis planned (that would not adequately remove Captisol®);
    2. severe cardiogenic or vasodilatory shock requiring two or more pressors that is not related to agent use;
    3. fulminant hepatic failure;
    4. no reasonable expectation of recovery (for instance, a likely outcome is persistent vegetative state) or life-expectancy, in the experience of the investigator, is less than 30 days.
  • Subjects who are being administered more than three third-line agents concomitantly or in whom the qualifying wean cannot be completed per protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
132 participants (actual)

Study arms

  • Active comparator
    SAGE-547

    Intravenous

    Drug: SAGE-547

  • Placebo comparator
    Placebo

    Intravenous

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Able to be Weaned Off All Third-Line Agents Prior to End of Double-Blind SAGE-547 or Placebo Infusion, and Remain Off All Third-Line Agents for ≥ 24 Hours Following the End of SAGE-547 or Placebo Infusion

    Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression electroencephalogram (EEG) pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG. A responder was a participant who was able to be weaned off all third-line agents prior to the end of the SAGE-547 or placebo infusion and remain off all third-line agents for \>=24 hours after the end of the study drug infusion. The primary analysis was a comparison between SAGE-547 and placebo of the proportion of responders.

    Time frame: 7 days

Secondary outcomes

  1. Time Between the Primary Outcome Response and the Re-institution of Any Third-line Agent for Seizure or Burst Suppression

    Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG. A responder was a participant who was able to be weaned off all third-line agents prior to the end of the SAGE-547 or placebo infusion and remain off all third-line agents for \>=24 hours after the end of the study drug infusion. The primary analysis was a comparison between SAGE-547 and placebo of the proportion of responders.

    Time frame: Up to 21 days

  2. Number of Participants Able to be Weaned Off All Third-line Agents Before the End of the First SAGE-547 or Placebo Infusion

    Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG.

    Time frame: Day 6

  3. Time Between the Secondary Outcome Measure Response and the Re-institution of Any Third-line Agent for Seizure or Burst Suppression

    Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG.

    Time frame: Up to 21 days

  4. Change in Clinical Global Impression Scale (CGI)

    The CGI scale was used to integrate several sources of information into a single rating of a participant's condition. The CGI was rated on a 7-point scale, from a minimum of 0 to a maximum of 7, where 0 = Not assessed; 1 = Normal, not at all ill; 2 = Borderline physically ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill participants. A negative change from baseline indicates improvement. A positive change from baseline indicates worsening. Here, study visits followed by "R" indicate the Open-label Treatment Period.

    Time frame: Up to 21 days

  5. Number of Days After the End of the First Study Drug Infusion Without Status Epilepticus, Up to Visit 12

    Here, study visits followed by "R" indicate the Open-label Treatment Period.

    Time frame: Up to 21 days

  6. Number of Days After the End of the First Study Drug Infusion Without Seizures (Convulsive and Non-convulsive), up to Visit 12

    Here, study visits followed by "R" indicate the Open-label Treatment Period.

    Time frame: Up to 21 days

  7. Number of Separate Episodes of Status Epilepticus Up to Visit 12

    Here, study visits followed by "R" indicate the Open-label Treatment Period.

    Time frame: Up to 21 days

  8. Number of Participants With a New Diagnosis of Epilepsy After Visit 11

    Here, study visits followed by "R" indicate the Open-label Treatment Period.

    Time frame: Up to 21 days

07

Results

Posted May 2, 2019

Participant flow

Participants took part in the study at 122 investigative sites in Canada, United States, Austria, Denmark, Estonia, Finland, France, Germany, Israel, Italy, Serbia, Spain and United Kingdom from 31 July 2015 to 11 August 2017.

Participant flow — Overall Study
MilestonePlaceboSAGE-547
Started6567
Intent-to-treat analysis set6666
Completed5053
Not completed1514
Withdrew: Completed visits but discontinued drug21
Withdrew: Died in double-blind treatment period1111
Withdrew: Adverse event11
Withdrew: Transferred away from study site10
Withdrew: Left study site for rehabilitation01

Outcome measures

PrimaryNumber of Participants Able to be Weaned Off All Third-Line Agents Prior to End of Double-Blind SAGE-547 or Placebo Infusion, and Remain Off All Third-Line Agents for ≥ 24 Hours Following the End of SAGE-547 or Placebo Infusion

Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression electroencephalogram (EEG) pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG. A responder was a participant who was able to be weaned off all third-line agents prior to the end of the SAGE-547 or placebo infusion and remain off all third-line agents for \>=24 hours after the end of the study drug infusion. The primary analysis was a comparison between SAGE-547 and placebo of the proportion of responders.

Time frame:
7 days
Reported as:
Count of participants · Participants
Number of Participants Able to be Weaned Off All Third-Line Agents Prior to End of Double-Blind SAGE-547 or Placebo Infusion, and Remain Off All Third-Line Agents for ≥ 24 Hours Following the End of SAGE-547 or Placebo Infusion
ParticipantsPlaceboSAGE-547
Number of Participants Able to be Weaned Off All Third-Line Agents Prior to End of Double-Blind SAGE-547 or Placebo Infusion, and Remain Off All Third-Line Agents for ≥ 24 Hours Following the End of SAGE-547 or Placebo Infusion2829
Statistical analysis
  • Placebo vs SAGE-547 · Regression, Logistic · p = 0.878 · Odds ratio (or): 1.056 · 95% CI 0.527 to 2.118
SecondaryTime Between the Primary Outcome Response and the Re-institution of Any Third-line Agent for Seizure or Burst Suppression

Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG. A responder was a participant who was able to be weaned off all third-line agents prior to the end of the SAGE-547 or placebo infusion and remain off all third-line agents for \>=24 hours after the end of the study drug infusion. The primary analysis was a comparison between SAGE-547 and placebo of the proportion of responders.

Time frame:
Up to 21 days
Reported as:
Median · days
Time Between the Primary Outcome Response and the Re-institution of Any Third-line Agent for Seizure or Burst Suppression
daysPlaceboSAGE-547
Time Between the Primary Outcome Response and the Re-institution of Any Third-line Agent for Seizure or Burst Suppression13.500 (0.06 to 18.00)14.000 (0.18 to 16.00)
Statistical analysis
  • Placebo vs SAGE-547 · Regression, Cox · p = 0.636 · Hazard ratio (hr): 0.747 · 95% CI 0.222 to 2.507
SecondaryNumber of Participants Able to be Weaned Off All Third-line Agents Before the End of the First SAGE-547 or Placebo Infusion

Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG.

Time frame:
Day 6
Reported as:
Count of participants · Participants
Number of Participants Able to be Weaned Off All Third-line Agents Before the End of the First SAGE-547 or Placebo Infusion
ParticipantsPlaceboSAGE-547
Number of Participants Able to be Weaned Off All Third-line Agents Before the End of the First SAGE-547 or Placebo Infusion4538
Statistical analysis
  • Placebo vs SAGE-547 · Regression, Logistic · p = 0.199 · Odds ratio (or): 0.623 · 95% CI 0.303 to 1.282
SecondaryTime Between the Secondary Outcome Measure Response and the Re-institution of Any Third-line Agent for Seizure or Burst Suppression

Third-line agents were anesthetic agents that were administered in order to reach a seizure or burst suppression EEG pattern. For this study, third-line agents were defined as continuous intravenous infusions of pentobarbital/thiopental, midazolam, propofol, and ketamine at maintenance doses alone or in combination sufficient to produce a burst or seizure suppression pattern on the EEG.

Time frame:
Up to 21 days
Reported as:
Median · days
Time Between the Secondary Outcome Measure Response and the Re-institution of Any Third-line Agent for Seizure or Burst Suppression
daysPlaceboSAGE-547
Time Between the Secondary Outcome Measure Response and the Re-institution of Any Third-line Agent for Seizure or Burst Suppression7.000 (0.00 to 20.00)15.000 (0.00 to 19.00)
Statistical analysis
  • Placebo vs SAGE-547 · Regression, Cox · p = 0.328 · Hazard ratio (hr): 0.683 · 95% CI 0.318 to 1.466
SecondaryChange in Clinical Global Impression Scale (CGI)

The CGI scale was used to integrate several sources of information into a single rating of a participant's condition. The CGI was rated on a 7-point scale, from a minimum of 0 to a maximum of 7, where 0 = Not assessed; 1 = Normal, not at all ill; 2 = Borderline physically ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill participants. A negative change from baseline indicates improvement. A positive change from baseline indicates worsening. Here, study visits followed by "R" indicate the Open-label Treatment Period.

Time frame:
Up to 21 days
Reported as:
Mean · units on scale
Change in Clinical Global Impression Scale (CGI)
units on scalePlaceboSAGE-547
Baseline6.0 ± 0.895.9 ± 1.31
Visit 12-1.0 ± 1.42-0.6 ± 1.91
Visit 12R-0.7 ± 1.36-0.5 ± 1.19
SecondaryNumber of Days After the End of the First Study Drug Infusion Without Status Epilepticus, Up to Visit 12

Here, study visits followed by "R" indicate the Open-label Treatment Period.

Time frame:
Up to 21 days
Reported as:
Mean · days
Number of Days After the End of the First Study Drug Infusion Without Status Epilepticus, Up to Visit 12
daysPlaceboSAGE-547
Visit 1210.05 ± 6.73811.15 ± 6.058
Visit 12R11.08 ± 6.5579.23 ± 6.345
Statistical analysis
  • Placebo vs SAGE-547 · Regression, Cox · p = 0.339 · Hazard ratio (hr): 0.583 · 95% CI 0.193 to 1.763
SecondaryNumber of Days After the End of the First Study Drug Infusion Without Seizures (Convulsive and Non-convulsive), up to Visit 12

Here, study visits followed by "R" indicate the Open-label Treatment Period.

Time frame:
Up to 21 days
Reported as:
Mean · days
Number of Days After the End of the First Study Drug Infusion Without Seizures (Convulsive and Non-convulsive), up to Visit 12
daysPlaceboSAGE-547
Visit 128.22 ± 7.2897.50 ± 6.626
Visit 12R7.52 ± 7.0546.08 ± 5.932
Statistical analysis
  • Placebo vs SAGE-547 · Regression, Cox · p = 0.817 · Hazard ratio (hr): 1.086 · 95% CI 0.539 to 2.189
SecondaryNumber of Separate Episodes of Status Epilepticus Up to Visit 12

Here, study visits followed by "R" indicate the Open-label Treatment Period.

Time frame:
Up to 21 days
Reported as:
Mean · episodes
Number of Separate Episodes of Status Epilepticus Up to Visit 12
episodesPlaceboSAGE-547
Visit 121.3 ± 0.501.4 ± 0.55
Visit 12R2.2 ± 2.171.0 ± 0.00
Statistical analysis
  • Placebo vs SAGE-547 · ANCOVA · p = 0.567 · Ls mean difference: -0.2 · 95% CI -0.9 to 0.5
SecondaryNumber of Participants With a New Diagnosis of Epilepsy After Visit 11

Here, study visits followed by "R" indicate the Open-label Treatment Period.

Time frame:
Up to 21 days
Reported as:
Count of participants · Participants
Number of Participants With a New Diagnosis of Epilepsy After Visit 11
ParticipantsPlaceboSAGE-547
Visit 1205
Visit 12R53

Adverse events

Collected over Up to approximately 27 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo12/65 (18.5%)22/65 (33.8%)58/65 (89.2%)
SAGE-54717/67 (25.4%)27/67 (40.3%)60/67 (89.6%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventPlaceboSAGE-547
Withdrawal of life supportSurgical and medical procedures7/6511/67
Cardiac arrestCardiac disorders4/655/67
PneumoniaInfections and infestations3/651/67
Brain herniationInjury, poisoning and procedural complications3/651/67
Septic shockInfections and infestations2/653/67
Diabetes insipidusEndocrine disorders2/650/67
SepsisInfections and infestations2/651/67
Status epilepticusNervous system disorders2/651/67
Subdural haematomaInjury, poisoning and procedural complications1/652/67
Brain oedemaNervous system disorders1/652/67
Most frequent other events
Showing 10 of 45
Most frequent other events
EventPlaceboSAGE-547
PyrexiaGeneral disorders21/6519/67
Urinary tract infectionInfections and infestations14/6513/67
Pleural effusionRespiratory, thoracic and mediastinal disorders8/6514/67
PneumoniaInfections and infestations11/6513/67
AnaemiaBlood and lymphatic system disorders7/6512/67
DiarrhoeaGastrointestinal disorders7/6512/67
HypokalaemiaMetabolism and nutrition disorders11/6510/67
HypotensionVascular disorders10/656/67
ConstipationGastrointestinal disorders8/6510/67
Decubitus ulcerSkin and subcutaneous tissue disorders8/655/67

Baseline characteristics

The Safety Analysis Set included all participants who had an infusion of blinded study drug initiated. One participant in the placebo group was erroneously given SAGE-547 and was, therefore, included in the SAGE-547 group.

Age, Continuous
Age, Continuous(years)PlaceboSAGE-547Total
Mean37.8 ± 22.6941.3 ± 23.8939.6 ± 23.29
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSAGE-547Total
Female303565
Male353267
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboSAGE-547Total
White474592
Black141327
Asian358
Other145
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboSAGE-547Total
Hispanic or Latino10616
Not Hispanic or Latino5561116
08

Study locations

171 sites
  • Sage Investigational Site
    Birmingham, Alabama 35233, United States
  • Sage Investigational Site
    Mobile, Alabama 36667, United States
  • Sage Investigational Site
    Phoenix, Arizona 85006, United States
  • Sage Investigational Site
    Phoenix, Arizona 85013, United States
  • Sage Investigational Site
    Little Rock, Arkansas 27702, United States
  • Sage Investigational Site
    Fresno, California 93721, United States
  • Sage Investigational Site
    Loma Linda, California 92354, United States
  • Sage Investigational Site
    Los Angeles, California 90027, United States
  • Sage Investigational Site
    Roseville, California 95661, United States
  • Sage Investigational Site
    Sacramento, California 95317, United States
  • Sage Investigational Site
    New Haven, Connecticut 06510, United States
  • Sage Investigational Site
    Wilmington, Delaware 19803, United States
  • Sage Investigational Site
    Washington D.C., District of Columbia 20010, United States
  • Sage Investigational Site
    Gainesville, Florida 32611, United States
  • Sage Investigational Site
    Jacksonville, Florida 32209, United States
  • Sage Investigational Site
    Miami, Florida 33155, United States
  • Sage Investigational Site
    Orlando, Florida 32803, United States
  • Sage Investigational Site
    Sarasota, Florida 34239, United States
  • Sage Investigational Site
    Tampa, Florida 33613, United States
  • Sage Investigational Site
    Weston, Florida 33331, United States
  • Sage Investigational Site
    Atlanta, Georgia 30303, United States
  • Sage Investigational Site
    Atlanta, Georgia 30322, United States
  • Sage Investigational Site
    Atlanta, Georgia 30342, United States
  • Sage Investigational Site
    Honolulu, Hawaii 96813, United States
  • Sage Investigational Site
    Honolulu, Hawaii 96826, United States
  • Sage Investigational Site
    Boise, Idaho 83706, United States
  • Sage Investigational Site
    Chicago, Illinois 60611, United States
  • Sage Investigational Site
    Chicago, Illinois 60612, United States
  • Sage Investigational Site
    Maywood, Illinois 60153, United States
  • Sage Investigational Site
    Peoria, Illinois 61637, United States
  • Sage Investigational Site
    Springfield, Illinois 62702, United States
  • Sage Investigational Site
    Urbana, Illinois 61801, United States
  • Sage Investigational Site
    Iowa City, Iowa 52242, United States
  • Sage Investigational Site
    Wichita, Kansas 67214, United States
  • Sage Investigational Site
    Lexington, Kentucky 40536, United States
  • Sage Investigational Site
    Louisville, Kentucky 40202, United States
  • Sage Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • Sage Investigational Site
    New Orleans, Louisiana 70115, United States
  • Sage Investigational Site
    Portland, Maine 04102, United States
  • Sage Investigational Site
    Baltimore, Maryland 21201, United States
  • Sage Investigational Site
    Baltimore, Maryland 21215, United States
  • Sage Investigational Site
    Boston, Massachusetts 02111, United States
  • Sage Investigational Site
    Boston, Massachusetts 02114, United States
  • Sage Investigational Site
    Boston, Massachusetts 02115, United States
  • Sage Investigational Site
    Boston, Massachusetts 02118, United States
  • Sage Investigational Site
    Boston, Massachusetts 02215, United States
  • Sage Investigational Site
    Newton, Massachusetts 02462, United States
  • Sage Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Sage Investigational Site
    Detroit, Michigan 48201, United States
  • Sage Investigational Site
    Detroit, Michigan 48202, United States
  • Sage Investigational Site
    East Lansing, Michigan 48824, United States
  • Sage Investigational Site
    Grand Rapids, Michigan 49503, United States
  • Sage Investigational Site
    Royal Oak, Michigan 48073, United States
  • Sage Investigational Site
    Minneapolis, Minnesota 55414, United States
  • Sage Investigational Site
    Rochester, Minnesota 55905, United States
  • Sage Investigational Site
    Jackson, Mississippi 39216, United States
  • Sage Investigational Site
    Kansas City, Missouri 64108, United States
  • Sage Investigational Site
    St Louis, Missouri 63110, United States
  • Sage Investigational Site
    Edison, New Jersey 08818, United States
  • Sage Investigational Site
    Morristown, New Jersey 08827, United States
  • Sage Investigational Site
    New Brunswick, New Jersey 08901, United States
  • Sage Investigational Site
    Summit, New Jersey 07901, United States
  • Sage Investigational Site
    Buffalo, New York 14203, United States
  • Sage Investigational Site
    New York, New York 10016, United States
  • Sage Investigational Site
    New York, New York 10029, United States
  • Sage Investigational Site
    New York, New York 10032, United States
  • Sage Investigational Site
    Port Jefferson, New York 11777, United States
  • Sage Investigational Site
    Rochester, New York 14642, United States
  • Sage Investigational Site
    Syracuse, New York 13210, United States
  • Sage Investigational Site
    Durham, North Carolina 27710, United States
  • Sage Investigational Site
    Winston-Salem, North Carolina 27157, United States
  • Sage Investigational Site
    Akron, Ohio 44308, United States
  • Sage Investigational Site
    Cincinnati, Ohio 45229, United States
  • Sage Investigational Site
    Cincinnati, Ohio 45267, United States
  • Sage Investigational Site
    Cleveland, Ohio 44195, United States
  • Sage Investigational Site
    Columbus, Ohio 43210, United States
  • Sage Investigational Site
    Toledo, Ohio 43614, United States
  • Sage Investigational Site
    Portland, Oregon 97213, United States
  • Sage Investigational Site
    Portland, Oregon 97225, United States
  • Sage Investigational Site
    Portland, Oregon 97239, United States
  • Sage Investigational Site
    Hershey, Pennsylvania 17033, United States
  • Sage Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Sage Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Sage Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • Sage Investigational Site
    Philadelphia, Pennsylvania 19141, United States
  • Sage Investigational Site
    Philadelphia, Pennsylvania 19147, United States
  • Sage Investigational Site
    Pittsburgh, Pennsylvania 15212, United States
  • Sage Investigational Site
    Charleston, South Carolina 29425, United States
  • Sage Investigational Site
    Memphis, Tennessee 38105, United States
  • Sage Investigational Site
    Nashville, Tennessee 37232, United States
  • Sage Investigational Site
    Austin, Texas 78723, United States
  • Sage Investigational Site
    Dallas, Texas 75251, United States
  • Sage investigational Site
    San Antonio, Texas 78229, United States
  • Sage Investigational Site
    Salt Lake City, Utah 84108, United States
  • Sage Investigational Site
    Salt Lake City, Utah 84113, United States
  • Sage Investigational Site
    Burlington, Vermont 05401, United States
  • Sage Investigational Site
    Seattle, Washington 98105, United States
  • Sage Investigational Site
    Huntington, West Virginia 25705, United States
  • Sage Investigational Site
    Morgantown, West Virginia 26506, United States
  • Sage Investigational Site
    Wauwatosa, Wisconsin 53226, United States

Showing the first 100 of 171 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Jul 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

Results were first posted in May 2019, 1 year 9 months after primary completion. A results delay was requested in Jul 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2015
First posted
Jun 23, 2015
Start
Jun 2015
Primary completionActual
Jul 18, 2017
CompletionActual
Aug 11, 2017
Results delay requested
Jul 18, 2018
Results first posted
May 2, 2019
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02477618
Responsible party
Sponsor
First posted
Jun 23, 2015
Start date
Jun 2015
Primary completion
Jul 18, 2017
Completion
Aug 11, 2017
Results posted
May 2, 2019
Last update
Oct 14, 2025

Study contacts

Eric Rosenthal, MD
principal investigator · Massachusetts General Hospital
Mark Wainwright, MD, PhD
principal investigator · Ann & Robert H Lurie Children's Hospital of Chicago

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexanolone

Start the discussion